Montpellier, February 26th 2024 – Since it was launched in 2021, 400 patients have already been treated with Epione®, Quantum Surgical’s platform, worldwide. Integrating robotics and artificial intelligence, it enables the curative and early treatment of tumors in the abdomen and in the lungs.
Epione® is a technology that allows physicians to perform safe and effective percutaneous tumor ablations, a minimally invasive treatment in which one or several needles are inserted through the skin to the tumor to destroy it.
400 patients have already benefited from this curative treatment worldwide, including in the United States where Quantum Surgical sold its first robot in December 2023.
“Our mission is to enable as many patients as possible to benefit from effective and high-value-added treatment, and the entire Quantum Surgical team is delighted that 400 of them have already been able to benefit from Epione® technology to treat their tumors and lesions. This exponential growth demonstrates the utility of our robot, both in the United States and in France,” says Bertin Nahum, President and Co-founder of Quantum Surgical.
Epione® is CE marked in Europe for abdomen and lung tumors, and FDA cleared for abdominal tumors. Epione® is also available at the Gustave Roussy Cancer Center in Villejuif, as well as at the Hospices Civils de Lyon and in Miami.
About Quantum Surgical
Quantum Surgical is a French medical robotics company founded in Montpellier. Its Epione® robotic percutaneous ablation platform is dedicated to the curative and early treatment of cancers. Quantum Surgical thus offers a new approach to cancer treatment by standardizing access to care. More patients can benefit from innovative, better targeted and less invasive treatments. Hundreds of patients have already been treated worldwide.
Co-founded in 2017 and with a team of 110+ employees, Quantum Surgical is based in Montpellier, with offices in Miami, Florida. Quantum Surgical received the Prix Galien USA in 2022, the equivalent of the Nobel Prize for biopharmaceutical research and joined in 2023 the governmental French Tech 2030 program in 2023 that supports top emerging actors in disruptive innovation.
More information: www.quantumsurgical.com
Press contact Quantum Surgical
Stéphanie Moy
s.moy@quantumsurgical.com
Tel.: +33 (0)6 32 55 85 48
